Rockwell Medical Inc (RMTI) Quote

RMTI..................................https://stockcharts.com/h-sc/ui?s=RMTI&p=W&b=5&g=0&id=p86431144783

RMTI, new 52 week low

RMTI........................................https://stockcharts.com/h-sc/ui?s=RMTI&p=W&b=5&g=0&id=p86431144783

RMTI.......................................https://stockcharts.com/h-sc/ui?s=RMTI&p=W&b=5&g=0&id=p86431144783

RMTI.......................................https://stockcharts.com/h-sc/ui?s=RMTI&p=W&b=5&g=0&id=p86431144783

RMTI..................................https://stockcharts.com/h-sc/ui?s=RMTI&p=W&b=5&g=0&id=p86431144783

RMTI.............................https://stockcharts.com/h-sc/ui?s=RMTI&p=W&b=5&g=0&id=p86431144783

RMTI..........................https://stockcharts.com/h-sc/ui?s=RMTI&p=W&b=5&g=0&id=p86431144783

RMTI............................................https://stockcharts.com/h-sc/ui?s=RMTI&p=W&b=5&g=0&id=p86431144783

Price targets are as low as $5. I'm in @ $1.22. The quarterly numbers have gotten better. I guess we will know on March 21st.Good luck

This thing has not been healthy in a while. I lost money on it last year, not sure why I’m even looking at it again. It took another major hit when they lowered guidance in January. The chart looks interesting, but charts don’t run on smoke and mirrors, they need material events to cause them to change directions. Watching - 4God

Press Release: Rockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024.
The numbers better be really good. If not it's lights out. They will end up on the OTC. GLTA

In @ $1.22

Recent news has stopped the bleeding. Expect Q3 numbers to lift the ppps here.

This thing got taken to the chopping block, but HC Wainwright may have pulled its bacon out of the fire.

Seems like they might dump 10 million shares at $1.39.

They beat estimates by almost double
Impressive outcome

rmti vs ther

Ther can be big,with good news

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

Going up quick

$RMTI: Shes havng a nice day today.... now $1.30


Nice run up there on the daily chart



GO $RMTI

New ceo trying to get back to basics...get the biz profitable without relying on Triferic.

Correct me if I'm wrong, but after the r/s the price should be 2.37 and it's 2.02 in pre-market which means it has dropped .35 in pre-market.

Premarket looks promising

Rock Bottom.

$RMTI is scheduled to present at Aegis Virtual Conference, on Wednesday, February 23rd at 1:30 - 2:00 PM ET.
https://ih.advfn.com/stock-market/NASDAQ/rockwell-medical-RMTI/stock-news/87292951/rockwell-medical-inc-to-present-at-aegis-virtual

RMTI NEWS " Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea
https://finance.yahoo.com/news/rockwell-medical-announces-regulatory-approval-141500983.html

UP 1% and starting to rise...News just our 25 mins ago...
Heavy Volume Picking up ...becoming heavier..

https://finance.yahoo.com/quote/RMTI?p=RMTI


Finviz
https://finviz.com/quote.ashx?t=RMTI


TradingView Buy Rated
https://www.tradingview.com/symbols/NASDAQ-RMTI/


$RMTI

Agreed....
Needs some news to sustain it.

Murocman

Needs some news to sustain it.

Murocman

Moving North for sure $$$$$$
$RMTI

$RMTI will have huge breakout from here, I think

We be going North $$$$$:) air !!!!

Good morning from miami fla
Why is this moving up anyone ?

Merry Christmas $$$$$$$:)

https://finance.yahoo.com/news/rockwell-medical-study-demonstrates-no-210100032.html

https://ih.advfn.com/stock-market/NASDAQ/rockwell-medical-RMTI/stock-news/86578594/rockwell-medical-study-demonstrates-no-drug-drug-i

A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

To submit questions in advance, please email your questions to invest@rockwellmed.com.

$RMTI

$RMTI Rockwell Medical, Inc. to Report Second Quarter 2021 Financial and Operating Results on August 16, 2021 https://finance.yahoo.com/news/rockwell-medical-inc-report-second-110000902.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo

$RMTI News July 29, 2021

Rockwell Medical, Inc. to Report Second Quarter 2021 Financial and Operating Results on August 16, 2021
https://finance.yahoo.com/news/rockwell-medical-inc-report-second-110000902.html

Green heading into the close!

RMTI

$RMTI trading at approximately 30% of its 10-day average volume...but it's trading green.

$RMTI will be able to tap into a largely under serviced patient pool...

$RMTI announced that it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (FDA) in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

Home infusion represents a large and rapidly growing segment of healthcare. Many patient groups requiring home infusion therapies suffer from chronic diseases that are associated with a high incidence of iron deficiency and anemia. For example, it is estimated that 40%-55% of all home parenteral nutrition patients are iron deficient. Current treatment patterns can be inadequate for patients on home infusion therapy with iron deficiency anemia, causing them to suffer extreme fatigue and can result in serious health risks, such as, poor immune function and heart failure.

PRODUCING AND DELIVERING HEMODIALYSIS CONCENTRATES AND ANCILLARY PRODUCTS TO DIALYSIS PROVIDERS

Rockwell Medical, $RMTI, is an innovative leader in producing and delivering hemodialysis concentrates (solutions and powders) along with related ancillary products to dialysis providers located throughout the U.S. and abroad.

Rockwell Medical is dedicated to providing the hemodialysis community with the highest quality products supported by the most reliable delivery service in the industry. Rockwell has multiple manufacturing locations throughout the United States to ensure fast and efficient delivery of our products. The company adheres to Good Manufacturing Practices (GMPs) and to the Association for Advancement of Medical Instrumentation (AAMI) standards in our manufacturing, ensuring a high-quality hemodialysate known throughout the industry for safety and excellence.

Our customer service department is dedicated to the fundamental principle that our customers are the most important part of our business. Our representatives strive to provide the highest level of courtesy and efficiency to our customers. Rockwell Medical is an independent supplier that does not own or operate dialysis clinics. Our focus is on providing customers with quality dialysis products.

https://www.rockwellmed.com/hemodialysis-concentrates/supporting-dialysis-providers/

$RMTI Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives.

The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. The Company is developing FPC for the treatment of iron deficiency in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting, a large and rapidly growing segment of healthcare, and where these patients suffer from chronic diseases associated with high incidence of iron deficiency and anemia.

In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.

Once we see updates from the FDA on this, $RMTI will see a great run...

“This is an important step for Rockwell Medical and home infusion patients as we believe that FPC is uniquely suited to address this important unmet clinical need,” said Russell Ellison, M.D., President and Chief Executive Officer of Rockwell Medical. “We expect to finalize our Phase 2 clinical study design and protocol with the advice and guidance of the FDA.”

RMTI

I found this page of the website interesting and informative, to help me understand why this technology is so special.

https://www.rockwellmed.com/our-technology/technology-platform/

PLATFORM TECHNOLOGY TO MANAGE IRON IN A NEW WAY
Ferric pyrophosphate citrate (FPC) is a novel complex iron salt, developed to replace iron losses in patients with anemia in an entirely new way. This unique and differentiated molecule consists of an iron atom complexed to one pyrophosphate and two citrate anions. This formulation has been shown to allow for rapid donation of iron to transferrin, protein in the blood that binds to iron and transports it through the body, including to the bone marrow. This mechanism uses the body’s own means to transport iron safely to tissues that need iron (i.e. red blood cells and muscle).

$RMTI a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (FDA) in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

Home infusion represents a large and rapidly growing segment of healthcare. Many patient groups requiring home infusion therapies suffer from chronic diseases that are associated with a high incidence of iron deficiency and anemia. For example, it is estimated that 40%-55% of all home parenteral nutrition patients are iron deficient. Current treatment patterns can be inadequate for patients on home infusion therapy with iron deficiency anemia, causing them to suffer extreme fatigue and can result in serious health risks, such as, poor immune function and heart failure.

Agreed, the $RTMI volume has decreased but the price action has been steady.

Nice support at these levels!

RMTI

It's an interesting new technology...$RMTI

In addition, FPC iron is delivered regardless of other underlying conditions which might otherwise block the release of iron. Some of the challenges of managing iron in sick patients, including inflammation, hepcidin block, and functional iron deficiency, can be overcome with FPC due to its ability to provide bioavailable iron.

FPC is highly soluble in water and, therefore, can be formulated for parenteral administration either by the dialysis solution or intravenously. As a result, this novel approach to iron management has the potential for application in the treatment of anemia in many disease states.